What began as an educational resource for Wisconsinites is now reaching participants across the country and around the world. The Wisconsin Alzheimer’s Disease Research Center’s (ADRC) Healthy Living with Mild Cognitive Impairment (MCI) educational program is drawing strong participation and positive feedback, connecting people across Wisconsin and beyond with science-backed education on brain health, Alzheimer’s disease prevention strategies and practical tools and resources to support living well with MCI.
Dr. Nathaniel Chin
Introducing Lecanemab, the Latest Alzheimer’s Disease Drug to Receive FDA Accelerated Approval
On the latest episode of the podcast, Dementia Matters, host Nathaniel Chin, MD, gives an overview of the new Alzheimer’s treatment Leqembi (lecanemab), and highlights results from the second and third phases of its clinical trials.
Dr. Nathaniel Chin discusses the FDA approval of Leqembi on WPR
Nathaniel Chin, MD, joined host Rob Ferrett on the call-in program “Central Time” on The Ideas Network of Wisconsin Public Radio. Chin discussed the recent FDA approval of the drug Leqembi (lecanemab) to help with early Alzheimer’s and answered callers’ questions.
The Chin Family
Dr. Nathaniel Chin chose to become a doctor because of his father, Moe Chin, who was a physician in his hometown of Watertown, Wisconsin. However, when his dad was diagnosed with Alzheimer’s disease, Dr. Chin changed his career focus to geriatrics and moved from California to Wisconsin to help his mother as a caregiver to his father. Although Dr. Chin’s father succumbed to the disease, he continues to honor his father’s memory through his work.